Marksans Pharma arm receives regulatory approval for Sennosides tablets, shares gain 6%

Marksans Pharma arm receives regulatory approval for Sennosides tablets, shares gain 6%Marksans Pharma Share Price | The Sennosides tablets are used to treat constipation as per the US government's MedlinePlus website. By Shloka Badkar May 19, 2025, 2:26:43 PM IST (Published)1 Min ReadShares of Marksans Pharma gained over 6% on Monday, May 19, as the company said its wholly-owned subsidiary Relonchem Limited in the United Kingdom received market authorisation for Sennosides 7.5 mg tablets from the UK Medicines and Healthcare Products Regulatory Agency.

The Sennosides tablets are used to treat constipation as per the US government's MedlinePlus website.

Last week, Relonchem had secured another market authorisation for its Gabapentin oral solution, 50 mg/ml, from the UKMHRA. It is used for the treatment of nerve pain and epilepsy.

Gabapentin is widely prescribed for the treatment of nerve pain and epilepsy, and the new oral solution format is particularly useful for patients who have difficulty swallowing tablets or capsules.

In March, the pharma company received approval for its manufacturing facility in Verna, Goa, from Australia’s Therapeutic Goods Administration (TGA).

The Australian regulator cleared the Goa-based facility to produce solid dosage forms—such as tablets and hard capsules—for the Australian market.

Shares of Marksans Pharma gained 6.08% to hit an intraday high of ₹256.08 apiece on Monday, May 19. The stock has gained 18% in the past month.

Also Read: Protean eGov shares remain 20% lower despite management assuring of no immediate impact on businessContinue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsMarksans Pharmashare market today